| Theme | Metastatic recurrence and prognosis after endoscopic treatment for early colorectal carcinoma | |
|---|---|---|
| Title | Metastatic recurrence and prognosis after endoscopic treatment of early colorectal cancer with protruded lesions | |
| Publish Date | 2019/06 | |
| Author | Tomoyuki Nakane | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Michita Mukasa | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Atsushi Hinosaka | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Shuhei Hukunaga | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Tsutomu Nagata | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Akihiro Oouchi | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Hidenori Tokuyasu | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Yoshio Kusaba | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| Author | Osamu Tsuruta | Digestive Disease Center and GI Endoscopy, Kurume University Hospital |
| [ Summary ] | A rise in the rate of people seeking routine medical checkups and an increased use of endoscopic examinations have allowed for the early detection of colorectal cancer in larger numbers than ever before. In addition, an increased use of endoscopic treatments, including endoscopic submucosal dissection (ESD), has reduced unnecessary additional surgical resections due to improved diagnostic capacity and appropriate depth diagnosis. Since most colorectal tumors undergoing endoscopic treatment are protruded lesions, we researched metastatic recurrence and prognosis after endoscopic treatment in literature related to these particular cases. Our research findings confirmed that, if surgeons choose treatment according to guidelines, perform additional surgical excision as necessary, and conduct proper follow-up observation, patients can enjoy a low metastatic recurrence rate and favorable 5-year survival rate. | |